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Abstract
Natural, synthetic and environmental estrogens have numerous effects on the development
and physiology of mammals. Estrogen is primarily known for its role in the development and
functioning of the female reproductive system. However, roles for estrogen in male fertility,
bone, the circulatory system and immune system have been established by clinical
observations regarding sex differences in pathologies, as well as observations following
menopause or castration. The primary mechanism of estrogen action is via binding and
modulation of activity of the estrogen receptors (ERs), which are ligand-dependent nuclear
transcription factors. ERs are found in highest levels in female tissues critical to
reproduction, including the ovaries, uterus, cervix, mammary glands and pituitary gland.
Since other affected tissues have extremely low levels of ER, indirect effects of estrogen, for
example induction of pituitary hormones that affect the bone, have been proposed. The
development of transgenic mouse models that lack either estrogen or ER have proven to be
valuable tools in defining the mechanisms by which estrogen exerts its effects in various
systems. The aim of this article is to review the mouse models with disrupted estrogen
signaling and describe the associated phenotypes.
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Reproductive phenotypes of estrogen receptor
knockout models
Estrogen has many roles in reproduction, and the genera-
tion of the estrogen receptor (ER)a and ERb knockout
(aERKO and bERKO) mice has further illustrated its roles
and mechanisms. Interestingly, both sexes of the aERKO
mice are infertile, whereas only the bERKO female has
shown impaired fertility. In the male aERKO mice, infertility
is due to deficits at several points in the reproductive
process, including severe reduction in sperm numbers
and lack of sperm function, as well as abnormal sexual
behavior. The seminiferous tubules of the aERKO testes
show progressive dilation that is accompanied by degen-
eration of the seminiferous epithelium (Fig. 1) [1•,2•].
Transplanted aERKO sperm was functional when devel-
oped in normal host testes [3••]. In contrast, the testes of
the bERKO mice appear normal (Fig. 1), and produce suf-
ficient and functional sperm to allow fertility, resulting inBreast Cancer Research    Vol 2 No 5 Hewitt et al
production of offspring in mice examined to date. There-
fore, ERa appears to be more critical than ERb in media-
tion of the estrogen actions necessary for maintenance of
healthy testicular structures and the somatic cell function
required for successful sperm maturation.
Normally, the female rodent reproductive tract grows and
matures in response to cycling ovarian hormones, including
estradiol. The growth and maturation of the epithelial
portion and the preparation of the stromal layer is thought
to be important for successful implantation and pregnancy
to occur. The infertility of the female aERKO mouse is due
in part to the insensitivity of the uterus to the mitogenic and
differentiative actions of estrogen [4••,5••] (Fig. 2). Micro-
scopic evaluation of the aERKO uterine tissue indicates
that all expected tissues are present but appear immature,
as illustrated by a reduced number of glands in the
endometrium (Fig. 3). ERa is thus not necessary for devel-
opment of the uterus, but is necessary for complete matu-
ration and function of the tissue. In contrast, the wild-type
and bERKO uteri are indistinguishable, and show normal
organization and development of the stromal, myometrial
and epithelial layers (Fig. 3), as well as glandular structures.
ERb is thus apparently not required for normal develop-
ment of the female reproductive tract. Furthermore, when
challenged with estrogenic compounds, the wild-type and
bERKO uteri respond comparably with increased weight
and epithelial development, while the aERKO uterus is
nonresponsive. The uterus of the bERKO mouse is fully
functional, as pregnancies are successfully carried to term
and delivered. The vaginal tissue of the bERKO female is
also similar in the wild type, with indications of cornification,
an estrogen response, whereas the vaginal tissue of the
aERKO female remains immature and is not cornified.
Ovary and ovarian hormones
Numerous intraovarian effects of locally synthesized estro-
gens have been described and postulated to be essential to
ovarian function, including modifications in ER levels [6],
DNA synthesis and cell proliferation [7–11], intercellular gap
junctions [12], and follicular atresia [13]. Estradiol is also
known to augment the actions of follicle-stimulating hormone
on granulosa cells, resulting in the maintenance of follicle-
stimulating hormone receptor levels [14,15] and the acquisi-
tion of luteinizing hormone (LH) receptor [16,17], an event
critical to successful ovulation. The intraovarian actions of
estradiol act to ultimately enhance follicular responsiveness
to gonadotropins, and thereby result in increased aromatase
activity and further estrogen synthesis [17,18]. Therefore,
given the many speculated intraovarian actions of 17b-estra-
diol, disruption of the respective ER genes may be expected
to result in distinct ovarian phenotypes.
The ovarian phenotypes are a major component of the
infertility in the aERKO mice and the subfertility in the
bERKO mice. The aERKO female does not ovulate, while
the  bERKO female is subfertile with reduced litter
numbers and smaller litter sizes compared with wild-type
littermates. Interestingly, although both ERa and ERb are
detected in the ovary, their localization differs with ERb in
the granulosa cells and ERa in the theca and interstitial
Figure 1
Pathology of adult aERKO and bERKO testes. Sections from wild-type
and ER-disrupted testes were stained with hematoxylin and eosin for
comparison of their pathology. The wild-type and bERKO testes are
indistinguishable, while the aERKO testis shows degeneration of the
testicular structures.
Figure 2
Gross morphology of adult ERKO female reproductive tracts.
Reproductive tracts dissected from wild-type and bERKO animals are
normal, while the aERKO uterus is immature and the ovaries are
enlarged and dark-colored due to hemorrhagic cysts.http://breast-cancer-research.com/content/2/5/345
cells of the ovary [19•] (Fig. 4). The differential expression
of these receptors makes compensatory activity of one
receptor in the absence of the other unlikely.
The hallmark phenotype of the aERKO female is the
enlarged hemorrhagic cystic ovary (Fig. 5), although the
prepubertal aERKO ovary looks similar to its wild-type lit-
termate. This phenotype begins to develop progressively
as the animal matures and is apparently due to a lack of
estradiol feedback inhibition in the pituitary, which results
in chronically elevated LH and subsequent hyperstimula-
tion of the ovary (Table 1). This indicates that ERa is
responsible for mediating the LH feedback inhibition in the
hypothalamic–pituitary axis. The constant LH stimulation in
the aERKO mice results in an abnormal endocrine envi-
ronment in the aERKO female, with elevated estradiol and
testosterone, and chronic preovulatory basal progesterone
levels (Table 1).
The bERKO ovaries produce normal serum levels of estra-
diol and testosterone, and the circulating serum gonado-
tropin levels are also normal (Table 2). However, the
bERKO ovaries function suboptimally, as illustrated by the
appearance of numerous unruptured follicles following
superovulation. Attempts to superovulate the bERKO
female results in some ovulation, but the number of
oocytes released is reduced compared with wild-type
females (Table 3). A role for ERb in ovulation is thus indi-
cated, but the mechanism is still being defined.
Mammary gland
The mammary gland develops and functions in response
to ovarian hormones, most notably estrogen and proges-
terone [20]. The female mammary gland is immature at
birth and consists of a mainly stromal tissue, with only a
rudimentary epithelial duct structure emanating from the
nipple. The ducts elongate in response to ovarian and
pituitary hormones, eventually filling the stromal tissue with
a branched tree-like structure. Lobular alveolar buds
develop along the length of these ducts during pregnancy
and differentiate into secretory lactational structures.
Transgenic knockout models have been very informative in
understanding the roles of estrogen and progesterone in
mammary gland development. The role of progesterone is
indicated by the lack of development of alveolar buds in the
progesterone receptor knockout mouse [21••]. Similarly,
the role for ERa is illustrated by the lack of pubertal growth
of the epithelial ductal rudiment in the aERKO female
despite elevated circulating serum estradiol levels [22,23]
Figure 3
Uterine and vaginal histology of adult ERKO mice. Histological analysis of the uterus (top panels) and vagina (bottom panels) shows the bERKO
tissue is indistinguishable from the wild type, showing the normal organization of the uterine tissue into the epithelial (Ep), stromal (St) and
myometrial (My) compartments. In contrast, the aERKO uterine tissue is composed of all three layers, yet they are all immature and hypoplastic.
Note also the glands are fewer in number. The vagina of the wild-type and bERKO mice is identical and cornified, indicating response to estrogen,
while the aERKO vagina shows no cornification. (Reproduced with permission from Couse and Korach [5••].)(Table 1 and Fig. 6). Transplantation of a wild-type pituitary
under the kidney capsule of an aERKO female resulted in
growth and development of the aERKO mammary epithe-
lium. Removal of ovarian steroids by castration prevented
the growth and development of mammary epithelium fol-
lowing pituitary transplant (Bocchinfuso et al, submitted).
Administration of progesterone together with estradiol to
an ovexed aERKO mouse resulted in alveolar development
and some ductal elongation (Bocchinfuso et al, submitted).
These observations indicate that the aERKO pituitary in the
absence of ovarian hormones is incapable of providing a
hormonal environment necessary for mammary develop-
ment. In addition, the aERKO mammary gland epithelium is
capable of responding with growth when a normally func-
tioning pituitary is present to provide the necessary signals
to the ovary and the mammary gland. Finally, it is apparent
that the secretion of ovarian hormones is a required
element of ductal elongation in the aERKO mouse. The
bERKO mammary gland is similar to wild-type littermates
[5••] (Fig. 6) and is functional because bERKO mothers are
able to nurse their litters. Our observations suggest that
ERb is not required for the structural and functional devel-
opment of the mammary gland.
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Figure 4
Localization of ERa and ERb protein in the ovary. Serial sections from
mouse ovary were stained with antibody to ERa (top panel) or ERb
(bottom panel). Note that ERb immunoreativity is confined to the
granulosa cells of the follicle, while ERa immunoreativity is localized in
the thecal and interstitial cells of the ovary. 
Figure 5
Ovarian pathology of the ERKO mice. Histological analysis of the wild-
type ovary shows normal follicular development and indications of
ovulation. The aERKO ovary shows large cystic structures and arrested
follicle development with no indication of ovulation, while the bERKO
ovary shows development of follicles is occurring but with little indication
of successful ovulation. 
Table 1
Serum hormone levels in adult wild-type and a aERKO mice
Female Male
Hormone Wild type aERKO Wild type aERKO
Gonadal steroids
Estradiol (pg/ml)† 29.5 ± 2.5 84.3 ± 12.5* 11.8 ± 3.4 12.9 ± 3.4
Progesterone (ng/ml)† 2.3 ± 0.6 4.0 ± 1.1 0.5 ± 0.3 0.3 ± 0.1
Testosterone (ng/ml) 0.4 ± 0.4 3.2 ± 0.6 9.3 ± 4.0 16.0 ± 2.3
Anterior pituitary
LH (ng/ml) 0.3 ± 0.04 1.7 ± 0.3* 2.4 ± 1.2 3.7 ± 0.7
FSH (ng/ml) 4.9 ± 0.6 5.4 ± 0.7 26.0 ± 1.4 30.0 ± 1.1
Prolactin (ng/ml) 18.8 ± 10.7 3.5 ± 1.3 ND ND
Data presented as mean ± standard error of the mean. ERKO, Estrogen receptor knockout; FSH, follicle stimulating hormone; LH, luteinizing
hormone; ND, not determined. †These values in the female are different than those reported by Couse et al [43•], which were carried out on pooled
sera. The values above are the means from assays on individual samples and therefore are more likely to reflect the true levels in the two
genotypes. * t-test, wild type versus ERKO, P < 0.001. Reproduced with permission from Couse and Korach [5••].Skeletal and cardiovascular tissue
Clinical as well as experimental data imply a role for estro-
gen as well as other endocrine factors in maintaining bone
mass. For example, menopause or castration increases the
rate of osteoporosis progression in women [24]. The ERKO
model is a very useful tool for elucidating the mechanism of
estrogen effects in bone and whether these effects are
mediated, directly or indirectly, through ERs. ERa is present
at very low levels in the bone cells. In the aERKO female,
the bone is normal in terms of density, but it is significantly
shorter and smaller in diameter in both sexes of the aERKO
mice. This indicates the possibility of a role for estrogen in
bone lengthening [5••]. A recent report has indicated
aERKO mice have insulin-like growth factor-1 levels 30%
lower than normal mice [25], which might account for the
shorter bone. However, the altered hormonal environment
(elevated estradiol and testosterone; see Table 1) as well as
the increased body weight of the aERKO mouse should
also be considered when interpreting this phenotype. The
aERKO males do show a decrease in bone mineral density,
a phenotype that is similar to one clinical case of estrogen
insensitivity in a man [26]. Our current evaluation of the
bones of the bERKO mouse shows no apparent difference
from the wild type (unpublished data), indicating the lack of
a major role for ERb in bone physiology.
A role for estrogen in the cardiovascular system has also
been implied by clinical observations correlating hormonal
status with cardiovascular disease risk factors [27]. Addi-
tionally, ER has been detected in the vasculature [28]. In
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Table 2
Phenotypes of a aERKO and b bERKO mice
Observation
Tissue aERKO bERKO
Testis Progressive dilation and degradation of tubules, low  Normal structure, normal sperm count and fertility
sperm count, nonfunctional sperm
Uterus Immature, unresponsive to estradiol Normal development and response to estrogen
Ovary Enlarged, hemorrhagic cysts, follicles arrested at  Subfertile, infrequent and inefficient ovulation; normal 
preantral stage, no corpora lutea, no ovulation, elevated  estrogen and T
serum estrogen and T levels
Mammary, female Ducts do not develop beyond epithelial rudiment at  Normal, fully functional. Able to nurse offspring
nipple, no alveolar development
Pituitary FSHb, LHb, aGSU, mRNAs all elevated, prolactin  Normal serum gonadotropin levels
mRNA reduced
Cardiovascular (male) Lower basal nitric oxide, estrogen protection in vascular  ?
injury not lost. Increase in calcium channels, delayed 
cardiac depolarization
Bone Shorter; female, smaller diameter; male, lower density Normal
Brain Male, no intromission, ejaculation decreased agression;  Normal sexual behavior
female, no receptive behaviors
ERKO, Estrogen receptor knockout; FSH, follicle-stimulating hormone; aGSU, gonadotrophin subunit alpha; LH, luteinizing hormone; 
T, testosterone.
Table 3
Fertility and superovulation data in the b bERKO female mice
Continuous mating results Superovulation results
Genotype n Litters/female Pups/litter n Mean Range
Wild type 6 2.8 ± 0.4 8.8 ± 2.5 10 33.7 ± 4.8 9–57
Heterozygous ND ND ND 11 52.5 ± 5.7* 20–77
bERKO 11 1.7 ± 1.0* 3.1 ± 1.8** 11 6.0 ± 1.5* 0–13
Data presented as mean ± standard error of the mean. ERKO, Estrogen receptor knockout; ND, not determined. Reproduced with permission from
Couse and Korach [5••]. * P < 0.05 and ** P < 0.001 Student’s two tailed t-test versus wild type.the aERKO male heart, an increased number of calcium
channels [29•] and an associated delay in cardiac depolar-
ization have been observed. In the aERKO vasculature,
lower basal nitric oxide activity is detected [30] and, inter-
estingly, the ability of estrogen to play a protective role in a
vascular injury model is not lost in the aERKO [31•] or the
bERKO [32•] mice. These observations suggest either
that each receptor can compensate for the loss of the
other or that another mechanism results in protection.
Progesterone action in the a aERKO female
The activities of estrogen and progesterone are inter-
dependent in the female reproductive cycle [33]. The level
of estrogen in the serum peaks just prior to ovulation. This
estrogen ‘spike’ acts upon the uterus, initiating growth and
maturation in preparation for pregnancy. Following ovula-
tion, the level of progesterone rises and prepares the
uterine stroma for implantation and decidualization, which
is a transformation of the stromal cells in response to appo-
sition of the conceptus. Both hormones have been shown
to be essential for successful ovulation and pregnancy to
occur. The actions of progesterone, like those of estrogen,
are mediated through a specific nuclear transcription
factor, the progesterone receptor (PR). Since the level of
PR is regulated, in part, by estrogen, the activity of proges-
terone in aERKO tissues has been studied to determine
whether disruption of aER signaling alters PR signaling.
These observations have been reported in detail [34••], but
will be summarized here. PR is present at a basal level in
the aERKO uterus at about 60% of the wild-type level, and
its mRNA is not increased by estrogen treatment. However,
this basal level of PR is sufficient to induce the mRNA of
the progesterone-responsive calcitonin and amphiregulin
genes. The aERKO uterus can also be induced to undergo
a decidual reaction in response to progesterone and physi-
cal trauma, indicating that PR is fully functional both bio-
chemically and physiologically, and is not dependent on
ERa for expression or function. Interestingly, the decidual
reaction is estrogen dependent in the wild-type mice, but
not in the aERKO mice.
The mammary gland also responds to progesterone, with
development of lobular alveolar structures in the epithelium
in preparation for lactation. Although the mammary epithe-
lium of the aERKO mouse is underdeveloped, it can be
stimulated with progesterone to develop lobular alveolar
structures, suggesting that although the PR is regulated by
estrogen, the basal level of PR present in the aERKO
mammary gland is sufficient to mediate progesterone
action. The necessity for estrogen induction of PR for prog-
esterone responsiveness is brought into question by these
observations. As reported previously [34••], it is possible
that the need for estrogen priming is lost in the aERKO
mice because of developmental differences. Although these
progesterone responses have not been characterized in the
bERKO mice, females can carry pregnancies to term and
lactate normally, implying that the ability of the uterus and
mammary gland to respond to progesterone is normal.
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Figure 6
Mammary gland whole mounts from ERKO mice. An adult bERKO
mouse displays a fully developed ductal network similar to the wild type.
In contrast, the aERKO mouse has only a rudimentary underdeveloped
epithelial duct (arrow).Ligand-independent signaling
Numerous studies have shown that nuclear steroid recep-
tors can be activated by membrane receptor pathways to
mediate genomic and physiologic responses in the
absence of steroid ligand (reviewed in [35••]). This mecha-
nism is initiated when growth factors bind to and activate
their membrane receptor, resulting in activation of a phos-
phorylation cascade, culminating in modulation of nuclear
receptor activity, most likely by phosphorylation of the
nuclear receptor protein. These studies are summarized
and described in detail elsewhere [36•]. In the case of
ERa, we have reported activation by either epidermal
growth factor (EGF) or insulin-like growth factor-1
[36•,37,38•,39–41]. The aERKO mouse has allowed us to
show that estrogen-like effects of EGF require the ERa in
vivo, as EGF induced PR mRNA and thymidine incorpora-
tion only in uteri from wild-type mice, indicating that the
aERKO mouse was totally unresponsive. Further bio-
chemical studies indicate that the EGF receptor is present
and the pathway is functional in the aERKO mouse, as
EGF induced cFOS, an EGF-responsive gene [36•].
Summary
The phenotypes observed in the aERKO and bERKO mice
illustrate the roles of ERa and ERb in both reproductive
and nonreproductive tissues. Although some phenotypes
are downstream results of the lack of estrogen signaling (ie
chronic LH stimulation of the aERKO ovary due to loss of
estrogen-mediated negative feedback regulation of LH in
the pituitary), we have learned a great deal about the roles
of ERa and ERb in development and physiology. Contin-
ued evaluation and characterization of the phenotypes of
both classical estrogen target tissues, as well as other
organ systems, should help to uncover previously uncon-
sidered links of estrogen and other signaling pathways.
Finally, our recent generation of mice lacking both ERs
(abERKO) will be useful in detecting any interaction
between these receptors or compensatory mechanisms of
one receptor in the absence of the other, as well as uncov-
ering nonreceptor-mediated estrogen actions [42••].
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